Robust Call Option Volumes Highlight Investor Optimism
On 27 July 2026, Divis Laboratories (NSE: DIVISLAB) emerged as one of the most actively traded stocks in the call options segment. The strike prices of ₹7,700 and ₹7,800 attracted the highest volumes, with 14,249 and 11,856 contracts traded respectively. This translates to a combined turnover exceeding ₹23.3 lakhs, underscoring strong speculative interest ahead of expiry.
The open interest at these strikes remains elevated, with 653 contracts at ₹7,700 and 602 contracts at ₹7,800, indicating sustained positioning rather than mere intraday speculation. Given the underlying stock price of ₹7,325.5, these strike prices represent out-of-the-money calls, suggesting traders are betting on a near-term rally above these levels.
Expiry Patterns and Strike Price Significance
The 28 July expiry is pivotal as it marks the end of the monthly options cycle, often accompanied by heightened volatility and volume. The concentration of call activity at the ₹7,700 and ₹7,800 strikes reflects a consensus that Divis Laboratories could breach these resistance levels imminently. The stock is currently trading just 1.59% below its 52-week high of ₹7,438.5, reinforcing the plausibility of such a move.
Market participants appear to be positioning for a breakout, buoyed by the stock’s technical strength. Divis Laboratories is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a robust uptrend. This technical backdrop supports the bullish call option activity observed.
Fundamental Upgrades Bolster Positive Sentiment
Adding to the positive momentum, Divis Laboratories was upgraded from a Hold to a Buy rating on 14 July 2026, with a Mojo Score of 71.0, reflecting improved fundamentals and growth prospects. The company’s large-cap status with a market capitalisation of ₹1,92,213 crores further enhances its appeal among institutional investors seeking stability alongside growth.
Despite a slight dip in delivery volumes by 7.34% compared to the five-day average, the stock remains liquid enough to support sizeable trades, with an average traded value of ₹4.87 crores over five days. This liquidity ensures that the surge in call option activity is backed by genuine market participation rather than thin trading.
Comparative Performance and Sector Context
On the day of analysis, Divis Laboratories posted a 1.02% gain, closely tracking the Pharmaceuticals & Biotechnology sector’s 1.14% rise and outperforming the Sensex’s 0.76% advance. This relative strength within its sector further validates the bullish positioning seen in the options market.
The stock’s recent trend reversal after two consecutive days of decline suggests renewed buying interest, which may propel it closer to or beyond the ₹7,700 and ₹7,800 call strike prices before expiry.
Implications for Investors and Traders
The pronounced call option activity at near-the-money strikes ahead of expiry is a clear indicator of market optimism. Investors with a bullish outlook on Divis Laboratories may consider this as confirmation of positive momentum, while traders might look to capitalise on potential volatility around expiry.
However, it is prudent to monitor open interest changes and price action closely, as any failure to breach these strike prices could lead to a rapid unwinding of positions and increased volatility. The stock’s strong fundamentals and technical indicators provide a supportive environment, but external factors such as sectoral developments or broader market shifts could influence outcomes.
Outlook and Strategic Considerations
Given the upgrade to a Buy rating and the stock’s proximity to its 52-week high, Divis Laboratories is well positioned for further gains. The active call option interest at ₹7,700 and ₹7,800 strikes suggests that market participants are pricing in a potential breakout in the short term.
Long-term investors may view this as an opportune moment to accumulate shares, while option traders could explore strategies such as bull call spreads or outright call buying to benefit from anticipated upward moves with defined risk.
Overall, the confluence of technical strength, fundamental upgrades, and concentrated call option activity paints a bullish picture for Divis Laboratories as it approaches the July expiry.
